Blinklab Limited · ASX:BB1
Blinklab — Brokers meet Biotech (March 2025)
36 slides from Blinklab's conference presentation, Mar 20, 2025
Slide 1: For Early and Accurate Diagnosis of Autism & ADHD
(ASX:BB1) For personal use only For Early and Accurate Diagnosis of Autism & ADHD Introducing an AI-powered smartphone platform for neurological testing Brokers meet Biotech, 20 March 2025 Henk-Jan Boele, MD PhD
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by BlinkLab Limited (ACN 652 901 703) (BlinkLab or Company) and contains background information about For personal use only BlinkLab’s current operations at the date of this presentation. The presentation is in summary form and does not purport to be al
Slide 3: Corporate Snapshot
Corporate Snapshot Next-Generation Digital Solutions for Neurodevelopmental Health CAPITAL STRUCTURE For personal use only ASX Code BB1 Shares on Issue 99.2M Options on Issue (31 December 2024) 39.5M Founders’/ Directors’ shareholding % 37% Market Cap (19 March 2025) $43.6M Cash (31 December 2024) $
Slide 4: What is Autism?
What is Autism? For personal use only Neurodevelopmental condition that affects how the brain processes sensory information. Autism can impact: • Social development • Language development • Sensory processing • Behavior and interests
Slide 5: Economic Burden of Autism in USA – $700B in 2024
Economic Burden of Autism in USA – $700B in 2024 "The economic burden is significant and alarming” 1 For personal use only Ø Prevalence has grown up to 2-4% among children2 Ø Autism healthcare expenses are soaring3 • USA: Costs for an autism diagnostic evaluation: $1,000 to $7,000 • USA: Lifetime co
Slide 6: NDIS Payments for Autism: A$8.4B in 2024
NDIS Payments for Autism: A$8.4B in 2024 NDIS payments for autism rise by more than 20% annually, with the largest share allocated to Supervised Independent Living (SIL). For personal use only Data extracted and visualized by BlinkLab. Extracted from National Disability Insurance Scheme (NDIS).
Slide 7: Early diagnosis and intervention enhance independent living skills
Consensus: Early diagnosis and intervention enhance independent living skills in children with autism. For personal use only Ø Recommendation by American Association for Psychiatry: “The AAP recommends that all children be screened for ASD at ages 18 and 24 months” Ø Total number of children born ea
Slide 8: The challenge: No medical test available for autism
The challenge: No medical test available for autism Governments and healthcare providers are on the lookout for disruptive technologies For personal use only Sources: Left up - The Australian 15 February 2014; Right down- Sydney University 6 February 2023, www.sydney.edu.au/brain-mind;
Slide 9: Autism diagnosis is expensive, inefficient, and often late
Autism diagnosis is expensive, inefficient, and often late The costly labor and time-intensive diagnostic evaluations are unnecessary for many children. For personal use only 1-3 years of uncertainty for family and child ? ? Occupational Parents Primary Care Neuro- Late autism Late Concerned or GP P
Slide 10: BlinkLab's digital solution accelerates path to diagnosis
BlinkLab’s digital solution accelerates path to diagnosis The costly labor and time-intensive diagnostic evaluations are unnecessary for many children. For personal use only Diagnosis in weeks to months ? ? Parents Primary Care Neuro- Early autism Early and personalized intervention Concerned or GP
Slide 11: BlinkLab's AI-enabled Smartphone-based Assessment
For personal use only BlinkLab’s AI-enabled Smartphone-based Assessment
Slide 12: BlinkLab PPI test – Neurotypical Control (4 years old)
BlinkLab PPI test – Neurotypical Control (4 years old) For personal use only Patent: PCT/US2021/058698 Video used with permission of caregiver
Slide 13: BlinkLab PPI test – Neurotypical Control (4 years old)
BlinkLab PPI test – Neurotypical Control (4 years old) For personal use only Patent: PCT/US2021/058698 Video used with permission of caregiver
Slide 14: BlinkLab PPI test – Autism Spectrum (2 years old)
BlinkLab PPI test – Autism Spectrum (2 years old) For personal use only Patent: PCT/US2021/058698 Video used with permission of caregiver
Slide 15: BlinkLab PPI test – Autism Spectrum (2 years old)
BlinkLab PPI test – Autism Spectrum (2 years old) For personal use only Patent: PCT/US2021/058698 Video used with permission of caregiver
Slide 16: Our patented solution: Neuroscience on a smartphone
Our patented solution: Neuroscience on a smartphone For personal use only Minuscule facial reflexes, evoked by our app, Evokes Facial Reflexes generate a digital biomarker for autism. By presenting visual and auditory stimuli during smartphone use. Computer Vision Facial features are tracked on the
Slide 17: Large Study Validates and Enhances BlinkLab's Accuracy in Detecting Autism
Large Study Validates and Enhances BlinkLab’s Accuracy in Detecting Autism in Children For personal use only Released on 18 November 2024 In a sample of 441 children, BlinkLab achieved a sensitivity of 91% and specificity of 85%
Slide 18: Our AI technology detects autism and ADHD
Our AI technology detects autism and ADHD For personal use only BlinkLab precisely measures sensory sensitivity in people with autism and ADHD.
Slide 19: BlinkLab Outperforms FDA-approved Digital Peers
BlinkLab Outperforms FDA-approved Digital Peers We are leaders in the digital diagnostics and therapeutics space For personal use only Sensitivity 91% 52%* 71% Specificity 85% 19%* 81% Smartphone-based Yes Yes No FDA approval No - 510(k) Yes - De Novo Yes - 510(k) * Calculated over all study complet
Slide 20: Study Design and Timeline for 510(k) Regulatory Trial
Study Design and Timeline for 510(k) Regulatory Trial Prospective, multicenter in US, double-blinded, within-subject comparison study. For personal use only Enroll children between 2-11 Q4 2024 - CRO assigned* years and sign ICF - IRB approval * - Pre-submission meeting with FDA* Q1 2025 - Onboarded
Slide 21: We are experts in science, tech and commercialization
We are experts in science, tech and commercialization For personal use only Henk-Jan Boele, CEO Anton Uvarov, COO Bas Koekkoek, CSO Peter Boele, CTO Executive director MD, PhD, Entrepreneur and MBA, PhD, Biotechnology Analyst PhD, Assistant Professor of MA, PhD candidate, Erasmus MC neuroscientist a
Slide 22: We are backed up by an expert advisory board
We are backed up by an expert advisory board For personal use only Company Chairman Company Director Company Director Scientific advisor Scientific advisor Scientific advisor Brian Leedman Jane Morgan Richard Hopkins Prof. Samuel Wang Prof. Chris De Zeeuw Prof. Javier Medina Experienced Chairman and
Slide 23: Investment Highlights
Investment Highlights Breakthrough AI-Powered Solution For personal use only Ø Rapid, accurate results for early detection and diagnosis of autism and ADHD Significant Need & Market Opportunity Ø Addressing $700B autism and $122B ADHD markets (USA), with global potential Clinically-Validated & Paten
Slide 24: For further information please contact
ASX:BB1 For personal use only For further information please contact: Henk-Jan Boele (MD, PhD) Brian Leedman Cofounder and CEO Non-Executive Chairman henkjan@blinklab.org brian@blinklab.org M: +31 (0) 611 132 247 M: +61 (0) 412 281 780 info@blinklab.org @BlinkLab.App @Blink_Lab BlinkLab Limited (ASX
Slide 25: The formal presentation concludes here
For personal use only The formal presentation concludes here. The following slides are for discussion and Q&A purposes only.
Slide 26: FY2025 Milestones Achieved
FY2025 Milestones Achieved Large-Scale Pivotal Study Validation Nov 2024 Study demonstrates 91% Sensitivity and 85% Specificity for For personal use only Dx1 tool – outperforming competitors Monash MAGNET Study Launch Secured participation with Monash University study on deep Nov 2024 phenotyping an
Slide 27: Important milestones
Important milestones News pipeline: Updates on regulatory studies on autism and ADHD and new partnerships For personal use only Milestone Timeframe Start of activities for FDA registrational study in autism *2Q 2024 Interim data from ADHD clinical study in EU *3Q 2024 Appointment of US based CRO to
Slide 28: R&D Pipeline
R&D Pipeline Our R&D pipeline is focused on obtaining FDA 510(k) clearance and EU regulatory approval for BlinkLab as a diagnostic adjunct for autism and ADHD. For personal use only Pre-clinical development Early clinical development Feasibility clinical studies Pivotal clinical studies Regulatory a
Slide 29: BlinkLab is collaborating with world-leading institutions
BlinkLab is collaborating with world-leading institutions Since our product launched in 2022, we have established global partnerships academic and clinical institutes. 2022 2023 2024 ongoing For personal use only Proof-of-concept of smartphone-based Princeton University neurometric evaluations. Mult
Slide 30: Optimizing AI and machine learning for BlinkLab Dx
Optimizing AI and machine learning for BlinkLab Dx Establishing academic partnerships is crucial not only for academic and clinical adoption, but also for training our ML models with diverse datasets that reflect real-world data. For personal use only PREVIOUS STUDIES CURRENT WORK Our binary AI clas
Slide 31: Why is early intervention key?
Why is early intervention key? Young brains have high plasticity, allowing therapies to shape neural connections, improve communication and social skills, and maximize long-term potential. For personal use only 2 years old 7 years old “Synaptic Pruning”
Slide 32: Binary classification using random-forest model
Binary classification using random-forest model gave us a sensitivity of 85% and specificity of 84%. For personal use only
Slide 33: BlinkLab App & Online Portal Fully-Developed
BlinkLab App & Online Portal Fully-Developed Validated in >12,000 subjects tested globally, including people with limited healthcare access For personal use only • Remote testing Enables accessible and global diagnostics. • Scalable solution Easily adaptable for clinical and diverse research needs.
Slide 34: BlinkLab to Participate in the Landmark Monash University MAGNET Project
BlinkLab to Participate in the Landmark Monash University Autism/ADHD MAGNET Project For personal use only News announcement 13 November 2024 • The MAGNET project is an ongoing large cohort study aiming to enroll 1,000 families with children diagnosed with autism, ADHD, or both autism and ADHD. • MA
Slide 35: First product to monitor the effect of therapy in real-time
First product to monitor the effect of therapy in real-time For personal use only Real-time drug monitoring offers a path to even larger recurring revenues via subscription-based models.
Slide 36: Intellectual property
Intellectual property Our patents prohibit other parties to conduct neurometric testing using mobile devices. For personal use only BlinkLab has consistently prioritized the development We are represented by the US-based law firm, Meagher Our portfolio comprises patents filed both by Princeton and p